Amendments to the Claims

1-12. (cancelled)

- 13. (new) A method of treating myocardial infarction, comprising administering an effective amount of a compound selected from the group consisting of GLP-1, GLP-1 analogs, GLP-1 derivatives to a patient in need thereof.
- 14. (new) The method of claim 13, wherein the compound is administered at a dose between 0.25 and 6 pmol/kg/min
- 15. (new) The method of claim 14, wherein the dose is between 0.5 to about 2.4 pmol/kg/min.
- 16. (new) The method of claim 15, wherein the dose is between 0.5 to about 1.2 pmol/kg/min.
- 17. (new) A method of treating myocardial infarction, comprising, administering an effective amount of a compound that exerts insulinotropic activity by interacting with the same receptor, or receptors, with which GLP-1, GLP-1 analogs, and GLP-1 derivatives interact in exerting their insulinotropic activity to a patient in need thereof.
- 18. (new) The method of claim 17 wherein the compound is administered at a dose between 0.25 and 6 pmol/kg/min.
- 19. (new) The method of claim 18 wherein the dose is between 0.5 to about 2.4 pmol/kg/min.
- 20. (new) The method of claim 19 wherein the dose is between 0.5 to about 1.2 pmol/kg/min.